Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brian Stevens

Physician Assistant, Surgical Lorain, OH Physician Assistant

NPI 1245288158 CMS profile 10705193

3600 Kolbe Rd, Suite 227, Lorain, OH 44053

Open in the dashboard

General payments

$12,584

421 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Stevens of Lorain, OH is reported in the CMS Open Payments database as having received $12,584 across 421 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $821 16
2024 General $2,939 19
2023 General $1,033 45
2022 General $4,959 170
2021 General $2,832 171

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Stevens
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Brian Stevens were reported at $821. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Brian Stevens Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,832 $111 $36–$285 $132
2022 $4,959 $126 $44–$350 $149
2023 $1,033 $137 $47–$355 $160
2024 $2,939 $146 $49–$384 $164
2025 $821 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $3,158 41 payments
  2. Tandem Diabetes Care, Inc. $2,357 10 payments
  3. Dexcom, Inc. $957 54 payments
  4. Novo Nordisk Inc $541 44 payments
  5. Lilly USA, LLC $467 33 payments
  6. Xeris Pharmaceuticals, Inc. $437 18 payments
  7. Amgen Inc. $380 17 payments
  8. AbbVie, Inc. $379 24 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $371 17 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $370 11 payments
  11. Other $3,165 152 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,978 410 payments
  2. Travel and Lodging $3,582 9 payments
  3. Education $24 2 payments
Products named General payments · program years 2021–2025
  1. MINIMED 770G $2,934 33 payments
  2. t:slim X2 Insulin Pump with Control-IQ $2,357 10 payments
  3. Dexcom G6 Transmitter $790 50 payments
  4. Ozempic $459 38 payments
  5. RYBELSUS $459 38 payments
  6. JARDIANCE $371 17 payments
  7. Kerendia $370 11 payments
  8. STEGLATRO $293 16 payments
  9. STEGLUJAN $274 15 payments
  10. GVOKE PFS $243 14 payments
  11. Other $6,252 334 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 74 drugs

Part D claims

5,129

Median for Physician Assistant: 241

Drug cost

$2,178,793

Median for Physician Assistant: $4,110

Branded share of claims

70.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 329 $373,836
Mounjaro Tirzepatide Brand 267 $343,146
Ozempic Semaglutide Brand 240 $277,391
Jardiance Empagliflozin Brand 227 $196,983
Farxiga Dapagliflozin Propanediol Brand 154 $160,492
Rybelsus Semaglutide Brand 60 $73,408
Tresiba Flextouch U-100 Insulin Degludec Brand 98 $73,235
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 40 $60,124
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 46 $51,519
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 360 $50,191

The 10 drugs with the highest cost, of 74 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$34,681

Medicare's payments for the services billed

Medicare patients

203

Average age 71

Services billed

1,449

125 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Arthritis 61%
Chronic kidney disease 50%
Ischemic heart disease 40%
Depression 36%
COPD 34%
Heart failure 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $168
$168 12 —
Qutenza
  • Averitas Pharma Inc. $145
$145 — —
TEPEZZA
  • Amgen Inc. $121
$121 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

421 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Surgical in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record